Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 17/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 17/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 17/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 14/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 7/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | PNP | P00491 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enprofylline SCHEMBL1817246 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7602847 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9791629 | 0.88 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Enprofylline SCHEMBL9438600 | 0.88 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7466316 | 0.87 | ADORA2A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL1373494 | 0.85 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL8124420 | 0.85 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3699117 | 0.84 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL383123 | 0.84 | ADORA2A (0.72) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL30488609 | 0.82 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2232 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | claimed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | claimed |
| WO-2022123511-A1 | A COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | WO | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| US-11324705-B2 | Transdermal drug delivery system | AVRO LIFE SCIENCES, INC. (CA) | 2022-05-10 | — | — | US | claimed |
| WO-2022023496-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-02-03 | — | — | WO | claimed |
| US-5424297-A | Adenosine dextran conjugates | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1995-06-13 | — | — | US | claimed |
| WO-1995010282-A1 | USE OF PHOSPHATASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF CHANNEL RELATED DISEASES | MCGILL UNIVERSITY (CA) | 1995-04-20 | — | — | WO | claimed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | claimed |
| EP-0480934-B1 | A SLIMMING PHARMACEUTICAL COMPOSITION | NYCOMED DAK AS (DK) | 1994-06-29 | — | — | EP | claimed |
| EP-0480934-A1 | A SLIMMING PHARMACEUTICAL COMPOSITION. | DAK LAB AS (DK) | 1992-04-22 | — | — | EP | claimed |
| WO-1991000730-A1 | A SLIMMING PHARMACEUTICAL COMPOSITION | DAK-LABORATORIET A/S (DK) | 1991-01-24 | — | — | WO | claimed |
| US-4777255-A | Process for preparing a purine derivative | AKTIEBOLAGET DRACO (SE) | 1988-10-11 | — | — | US | claimed |
| EP-0282537-A1 | A NEW SYSTEM FOR ADMINISTRATION OF LIPOSOMES TO MAMMALS | Aktiebolaget Draco (SE) | 1988-09-21 | — | — | EP | claimed |
| WO-1988001862-A1 | A NEW SYSTEM FOR ADMINISTRATION OF LIPOSOMES TO MAMMALS | AKTIEBOLAGET DRACO (SE) | 1988-03-24 | — | — | WO | claimed |
| EP-0260241-A1 | A new system for administration of liposomes to mammals | Aktiebolaget Draco (SE) | 1988-03-16 | — | — | EP | claimed |